MP04-13 VALIDATION OF THE PROSTATE CANCER PREVENTION TRIAL RISK CALCULATOR 2.0 IN MULTIPARAMETRIC MRI ERA (2016)

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History I1 Apr 2016MP04-13 VALIDATION OF THE PROSTATE CANCER PREVENTION TRIAL RISK CALCULATOR 2.0 IN MULTIPARAMETRIC MRI ERA Michele Fascelli, John DiBianco, Christopher Bayne, Arvin George, M. Minhaj Siddiqui, Thomas Frye, Amichai Kilchevsky, Alice Semerjian, Maria Merino, Baris Turkbey, Bradford Wood, and Peter Pinto Michele FascelliMichele Fascelli More articles by this author , John DiBiancoJohn DiBianco More articles by this author , Christopher BayneChristopher Bayne More articles by this author , Arvin GeorgeArvin George More articles by this author , M. Minhaj SiddiquiM. Minhaj Siddiqui More articles by this author , Thomas FryeThomas Frye More articles by this author , Amichai KilchevskyAmichai Kilchevsky More articles by this author , Alice SemerjianAlice Semerjian More articles by this author , Maria MerinoMaria Merino More articles by this author , Baris TurkbeyBaris Turkbey More articles by this author , Bradford WoodBradford Wood More articles by this author , and Peter PintoPeter Pinto More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1948AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPTRC2.0) represents a widely used tool developed to identify men for PSA testing or prostate biopsy. PCPTRC2.0 has been assessed in previous trials with traditional methodologies for identifying prostate cancer (PCa). The accuracy of the PCPTRC2.0 in correctly identifying patients at risk for PCa has been called into question, particularly in patients undergoing MRI/US fusion prostate biopsies. We aim to assess the accuracy of the PCPTRC2.0 estimation in identifying PCa in an MRI-US fusion biopsy cohort. METHODS A review of men studied prospectively with MRI/US fusion biopsy was conducted. Between August 2007 and February 2014, 595 MRI/US fusion prostate biopsies were selected. Patients′ complete data was used to calculate their PCPTRC2.0 scores using the PCPTRC2.0 R-code. Risk of positive biopsy and high-grade (Gleason≥7) cancer on biopsy was calculated for each patient. Receiver operating characteristic (ROC) curves were analyzed and areas under the curve (AUC) were compared using DeLong′s test. RESULTS Of 595 men included in the study, cancer was detected in 39% (232) by systematic biopsy compared to 48% (287) on MRI-targeted biopsy alone. Median age was 62.3 years with a mean PSA of 12.0. The AUCs for overall cancer detection rate (CDR) were similar at 0.69 and 0.70 for systematic and MRI-targeted biopsy, respectively (p=0.69) [Figure 1a]. For high-grade disease according to the PCPTRC2.0 calculator, AUCs increased to 0.71 and 0.73 for systematic and MRI-targeted biopsy, but remained not statistically different (p=0.54) [Figure 1b]. CONCLUSIONS PCPTRC2.0 represents a valid prostate cancer prediction tool in men undergoing multiparametric MRI and fusion-guided prostate biopsy. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e33 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Michele Fascelli More articles by this author John DiBianco More articles by this author Christopher Bayne More articles by this author Arvin George More articles by this author M. Minhaj Siddiqui More articles by this author Thomas Frye More articles by this author Amichai Kilchevsky More articles by this author Alice Semerjian More articles by this author Maria Merino More articles by this author Baris Turkbey More articles by this author Bradford Wood More articles by this author Peter Pinto More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...